FMI
SYRE icon

F/M Investments’s Spyre Therapeutics SYRE Stock Holding History

F/M Investments’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.22M Sell
92,618
-6,842
-7% -$499K 0.42% 54
2026
Q1 		$5.02M Sell
99,460
-4,258
-4% -$161K 0.33% 63
2025
Q4 		$3.4M Buy
103,718
+48,825
+89% +$1.28M 0.13% 180
2025
Q3 		$920K Buy
54,893
+2,347
+4% +$38.3K 0.04% 298
2025
Q2 		$787K Buy
52,546
+702
+1% +$10.4K 0.03% 306
2025
Q1 		$837K Buy
51,844
+3,038
+6% +$63.2K 0.03% 303
2024
Q4 		$1.14M Buy
+48,806
New +$1.43M 0.04% 277

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

F/M Investments's SYRE Position: Q2 2026 in Review

F/M Investments reduced its Spyre Therapeutics (SYRE) stake by 6.9% in Q2 2026, selling an estimated $499K and leaving 92,618 shares worth $8.22M. The position accounts for 0.42% of the portfolio, ranked #54.

F/M Investments first reported a position in SYRE in Q4 2024 and has held it in 7 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • F/M Investments held 92,618 shares of Spyre Therapeutics worth $8.22M as of Q2 2026.
  • F/M Investments sold 6,842 Spyre Therapeutics shares in Q2 2026, an estimated $499K.
  • Spyre Therapeutics made up 0.42% of F/M Investments's portfolio in Q2 2026, its #54 holding.
  • F/M Investments first reported a position in Spyre Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on F/M Investments's 13F filing for Q2 2026, filed 5 Aug 2026.